CompletedPhase 3NCT02267226
Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery
Studying Congenital fibrinogen deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Octapharma
- Principal Investigator
- Cristina Solomon, MDOctapharma
- Intervention
- Octafibrin(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2014 – 2018
Study locations (12)
- Miami Children's Hospital, Miami, Florida, United States
- Dept of Clinical Hematology for Hemorrhagic Diatheses and Anaemia, SHAT "Joan Pavel", Sofia, Bulgaria
- St. John's Medical College Hospital, Bangalore, India
- Sahyadri Specialty Hospital, Pune, India
- Dept of Hematology, Christian Medical College, Vellore, India
- Seyed Al Shohada Hospital, Isfahan, Iran
- Dastgheib Hospital, Shīrāz, Iran
- Hotel-Dieu de France, Beirut, Lebanon
- Haematological Scientific Center of Ministry of Healthcare of the Russian Federation, Moscow, Russia
- Centre of Excellence in Thrombosis & Hemostasis, King Saud University, Riyadh, Saudi Arabia
- Dept of Haematology, Ege University Children's Hospital, Izmir, Turkey (Türkiye)
- Centre for Haemostasis & Thrombosis, St Thomas' Hospital, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02267226 on ClinicalTrials.govOther trials for Congenital fibrinogen deficiency
Additional recruiting or active studies for the same condition.